ERX-208 potency in Ovarian Cancer

San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity is dependent on LIPA expression. The data support the advancement of ERX-208 towards clinical trials in ovarian cancer.